Mancini Anthony Sells 1,774 Revolution Medicines (RVMD) Shares at $199.30 Each

Mancini Anthony, a leader at Revolution Medicines, Inc. (RVMD), sold 1,774 shares of the company at $199.30 per share, totaling $353,449, on September 19, 2026.

Who is Mancini Anthony and What is His Real Role at Revolution Medicines, Inc.?

The SEC Form 4 filing indicates that Mancini Anthony is among the insiders at Revolution Medicines, Inc., but the "Role" field only states "See Remarks," meaning the details of his position are included in the remarks section of the filing. This lack of specificity in the main table does not undermine the fact that he holds a leadership or administrative role, categories that provide access to non-public information.

Leaders, administrators, and any other executives who can influence the company's strategy are legally required to disclose their securities transactions. This obligation stems from the principle of market transparency, aimed at preventing insider trading abuses and ensuring equal treatment among investors.

As an insider, Mancini Anthony has visibility into projects, clinical trials, licensing agreements, and funding decisions that have not yet been made public. This position carries the responsibility to adhere to Securities and Exchange Commission (SEC) rules regarding insider transactions.

Transaction Details: 1,774 Shares at $199.30 Each

On September 19, 2026, Mancini Anthony transferred ownership of 1,774 Revolution Medicines, Inc. shares at a per-share price of $199.30. The gross amount received was $353,449, calculated by multiplying the number of shares by the per-share price, excluding any potential brokerage fees or taxes.

This transaction represents a secondary market sale, meaning the shares were sold to an external buyer rather than in the context of a new stock issuance by the company. The $199.30 price reflects the stock price on the transaction date, as recorded on the markets where RVMD is listed.

Why Insiders Sell Their Shares — Possible Reasons

Portfolio diversification is a common motivation for executives who want to reduce their exposure to a single company, even if they remain confident in its prospects. By selling a portion of their shares, they balance the overall risk of their holdings.

Tax planning can also encourage the sale of shares, particularly when an executive anticipates an increase in their tax liability or wishes to realize capital gains before the end of a fiscal year. Selling allows them to manage the timing of their tax obligations.

Personal liquidity needs, such as funding real estate projects, paying off debt, or covering significant expenses, also provide plausible explanations. Converting shares into cash offers immediate flexibility without resorting to borrowing.

A bearish signal perceived by the market can result from observing an insider sale, but it's important to note that the decision to sell does not necessarily reflect a negative view of the company's future performance. The reasons mentioned earlier are equally likely to explain the move.

Finally, strategic capital reallocation, such as shifting from shares to other asset classes (bonds, real estate, diversified funds), is a common practice among executives seeking to optimize the long-term performance of their savings.

How Individual Investors Monitor Form 4 Filings

The official SEC website, EDGAR, offers a free search engine where individuals can view Form 4 filings by entering the ticker RVMD or the insider's name. The documents are available in PDF or HTML format, with a two-day waiting period after the transaction.

Third-party platforms, such as OpenInsider, WhaleWisdom, or MarketWatch, aggregate Form 4 data and present it in filterable tables, facilitating daily monitoring for individual investors. These tools often provide email or mobile notifications when new insider transactions are recorded.

However, it's important to remember that Form 4 filings only include the number of shares, price, and transaction date. They do not specify underlying motivations or any contractual constraints that might influence the insider's decision. Therefore, investors should combine Form 4 analysis with other information sources, such as quarterly reports, press releases, and sector analyses, to form an informed opinion.